copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Enhancing drug delivery to the lungs to make every breath count Founded in 2004, LIQUIDIA CORPORATION (NASDAQ: LQDA) is a biopharmaceutical company dedicated to the development and commercial-ization of best-in-class therapies with the potential to improve the standard of care for patients with different pulmonary diseases
Liquidia Corporation to Host R D Day in New York City on October 28, 2025 The event will feature presentations from Liquidia’s management team alongside three key opinion leaders (KOLs) in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) The agenda will focus on L606 (treprostinil liposome inhalation suspension), an investigational sustained-release formulation, and include a
Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary . . . MORRISVILLE, N C , Jan 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare . . . MORRISVILLE, N C , Aug 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company’s executive leadership team will be providing an update on the company's business during a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, beginning at 3:45 p m ET in Boston
Liquidia Corporation Announces Chief Executive Officer Transition December 14, 2020 RESEARCH TRIANGLE PARK, N C , Dec 14, 2020 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Damian deGoa has been appointed as Chief Executive Officer (CEO) and a director of the Company, effective immediately He succeeds Neal F Fowler who has retired as CEO and a director of the Company Mr Fowler has agreed to provide assistance to the Company for
Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net . . . MORRISVILLE, N C , Jan 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIATM (treprostinil) inhalation powder, as well as updates on the commercial
Liquidia Corporation Announces Raise of $67. 5 Million from New Common . . . The Company offered 6,460,674 shares of common stock in the public offering at a price of $8 90 per share In addition, Liquidia entered into a common stock purchase agreement with funds managed by Caligan Partners LP for the sale of 1,123,595 shares of common stock at a purchase price of $8 90 per share in a private placement exempt from the registration requirements of the Securities Act of
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging . . . July 24, 2020 RESEARCH TRIANGLE PARK, N C , July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics Corporation (UTC) filed an amended complaint in its patent infringement
Liquidia Announces Poster Presentation at the 14th Annual World . . . RESEARCH TRIANGLE PARK, N C , Jan 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc (Nasdaq:LQDA) ( Liquidia ), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that it will present a poster highlighting clinical data from studies of LIQ861, treprostinil inhalation